Erratum: Tumour expression of leptin is associated with chemotherapy resistance and therapy-independent prognosis in gastro-oesophageal adenocarcinomas (British Journal of Cancer (2014) 110 (1525-1534) DOI: 10.1038/bjc.2014.45);Tumour expression of leptin is associated with chemotherapy resistance and therapy-independent prognosis in gastro-oesophageal adenocarcinomas

British Journal of Cancer

Volumn 110, Issue 6, 2014, Pages 1525-1534

  Bain, G H ^a,b   Collie Duguid, E ^a   Murray, G I ^a,b   Gilbert, F J ^c   Denison, A ^a,b   McKiddie, F ^b   Ahearn, T ^b   Fleming, I ^a   Leeds, J ^b   Phull, P ^b   Park, K ^b   Nanthakumaran, S ^b   Grabsch, H I ^d   Tan, P ^e   Welch, A ^a   Schweiger, L ^a   Dahle Smith, A ^a,b   Urquhart, G ^a   Finegan, M ^a   Petty, R D ^a,b  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d UNIVERSITY OF LEEDS   (United Kingdom)

^e NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

gastro oesophageal adenocarcinoma; gene expression profiling; immunohistochemistry; leptin; predictive biomarker; prognostic biomarker

Indexed keywords

479306 1G; CISPLATIN; F 6627 1G; FLUOROURACIL; LEPTIN; O 9512; OXALIPLATIN; UNCLASSIFIED DRUG;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHEMOSENSITIVITY; CONTROLLED STUDY; ESOPHAGEAL ADENOCARCINOMA; FEMALE; GASTRO OESOPHAGEAL ADENOCARCINOMA; GENE EXPRESSION PROFILING; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANK SUM TEST; SIGNAL TRANSDUCTION; STOMACH ADENOCARCINOMA; TUMOR BIOPSY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CELL GROWTH PROCESSES; DRUG RESISTANCE, NEOPLASM; ESOPHAGEAL NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; LEPTIN; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RNA, MESSENGER; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84896494370     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2015.391     Document Type: Erratum

References (42)

1. Abdel-Fatah TMA, Perry C, Dickinson P, Ball G, Moseley P, Madhusudan S, Ellis IO, Chan SYT (2013) Bcl2 is an independent prognostic marker of triple negative breast cancer (TNBC) and predicts response to anthracycline combination (ATC) chemotherapy (CT) in adjuvant and neoadjuvant settings. Ann Oncol 24(11): 2801-2807.
2. Abnet CC, Freedman ND, Hollenbeck AR, Fraumeni Jr. JF, Leitzmann M, Schatzkin A (2008) A prospective study of BMI and risk of oesophageal and gastric adenocarcinoma. Eur J Cancer 44: 465-471.
3. Bang Y, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J, Kang Y (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet Oncol 376: 687-697.
4. Beales ILP, Ogunwobi OO (2007) Leptin synergistically enhances the anti-apoptotic and growth-promoting effects of acid in OE33 oesophageal adenocarcinoma cells in culture. Mol Cell Endocrinol 274: 60-68.
5. Bjorbaek C, Kahn BB (2004) Leptin signaling in the central nervous system and the periphery. Recent Prog Horm Res 59: 305-331.
6. Cunningham D, Allum W, Stenning S, Thompson J, VandeVelde CH, Nicolson M, Scarffe JH, Lofts F, Falk S, Iveson T, Smith D, Langley R, Verma M, Weeden S, Chua Y. the MAGIC Trial Participants (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355: 11-20.
7. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Norman AR (2008) Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358: 36-46.
8. Dong Z, Xu X, Du L, Yang Y, Cheng H, Zhang X, Li Z, Wang L, Li J, Liu H, Qu X, Wang C (2013) Leptin-mediated regulation of MT1-MMP localization is KIF1B dependent and enhances gastric cancer cell invasion. Carcinogenesis 34: 974-983.
9. Duncan R, Carpenter B, main LC, Telfer C, Murray GI (2008) Characterisation and protein expression profiling of annexins in colorectal cancer. Br J Cancer 98: 426-433.
10. Edgren G, Adami H, Weiderpass E, Nyrén O (2012) A global assessment of the oesophageal adenocarcinoma epidemic. Gut 62(10): 1406-1414.
11. Ferla R, Bonomi M, Otvos Jr L, Surmacz E (2011) Glioblastoma-derived leptin induces tube formation and growth of endothelial cells: comparison with VEGF effects. BMC Cancer 11: 303.
12. Ferry DR, Anderson M, Beddard K, Tomlinson S, Atherfold P, Obszynska J, Harrison R, Jankowski J (2007) A phase II study of gefitinib monotherapy in advanced esophageal adenocarcinoma: evidence of gene expression, cellular, and clinical response. Clin Cancer Res 13: 5869-5875.
13. Geng Y, Wang J, Wang R, Wang K, Xu Y, Song G, Wu C, Yin Y (2012) Leptin and HER-2 are associated with gastric cancer progression and prognosis of patients. Biomed Pharmacother 66(6): 419-424.
14. Gertler A, Solomon G (2013) Leptin-activity blockers: development and potential use in experimental biology and medicine. Can J Physiol Pharmacol 91: 873-882.
15. Hope NR, Murray GI (2011) The expression profile of RNA-binding proteins in primary and metastatic colorectal cancer: relationship of heterogeneous nuclear ribonucleoproteins with prognosis. Hum Pathol 42: 393-402.
16. Howard JM, Beddy P, Ennis D, Keogan M, Pidgeon GP, Reynolds JV (2010) Associations between leptin and adiponectin receptor upregulation, visceral obesity and tumour stage in oesophageal and junctional adenocarcinoma. Br J Surg 97: 1020-1027.
17. Huang DW, Sherman BT, Lempicki RA (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4: 44-53.
18. Ichikawa W, Sasaki Y (2006) Correlation between tumor response to first-line chemotherapy and prognosis in advanced gastric cancer patients. Ann Oncol 17: 1665-1672.
19. Ivanova T, Zouridis H, Wu Y, Cheng LL, Tan IB, Gopalakrishnan V, Ooi CH, Lee J, Qin L, Wu J, Lee M, Rha SY, Huang D, Liem N, Yeoh KG, Yong WP, Teh BT, Tan P (2013) Integrated epigenomics identifies BMP4 as a modulator of cisplatin sensitivity in gastric cancer. Gut 62: 22-33.
20. Kelsen DP, Winter KA, Gunderson LL, Mortimer J, Estes NC, Haller DG, Ajani JA, Kocha W, Minsky BD, Roth JA, Willett CG (2007) Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol 25: 3719-3725.
21. Kim HS (2009) Leptin and leptin receptor expression in breast cancer. Cancer Res Treat 41: 155-163.
22. Kunz PL, Gubens M, Fisher GA, Ford JM, Lichtensztajn DY, Clarke CA (2012) Long-term survivors of gastric cancer: a California population-based study. J Clin Oncol 30: 3507-3515.
23. Lordick F, Kang Y, Chung H, Salman P, Oh SC, Bodoky G, Kurteva G, Volovat C, Moiseyenko VM, Gorbunova V, Park JO, Sawaki A, Celik I, Götte H, Meleźinková H, Moehler M (2013) Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol 14: 490-499.
24. Mandard A, Dalibard F, Mandard J, Marnay J, Henry-Amar M, Petiot J, Roussel A, Jacob J, Segol P, Samama G, Ollivier J, Bonvalot S, Gignoux M (1994) Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer 73: 2680-2686.
25. Miyoshi Y, Funahashi T, Tanaka S, Taguchi T, Tamaki Y, Shimomura I, Noguchi S (2006) High expression of leptin receptor mRNA in breast cancer tissue predicts poor prognosis for patients with high, but not low, serum leptin levels. Int J Cancer 118: 1414-1419.
26. Nejati-Koshki K, Zarghami N, Pourhassan-Moghaddam M, Rahmati-Yamchi M, Mollazade M, Nasiri M, Esfahlan RJ, Barkhordari A, Tayefi-Nasrabadi H (2012) Inhibition of leptin gene expression and secretion by silibinin: possible role of estrogen receptors. Cytotechnology 64: 719-726.
27. Ogunwobi O, Mutungi G, Beales ILP (2006) Leptin stimulates proliferation and inhibits apoptosis in Barrett's esophageal adenocarcinoma cells by cyclooxygenase-2-dependent, prostaglandin-E2-mediated transactivation of the epidermal growth factor receptor and c-Jun NH2-terminal kinase activation. Endocrinology 147: 4505-4516.
28. Ohtsu A, Shah MA, Van Cutsem E, Rha SY, Sawaki A, Park SR, Lim HY, Yamada Y, Wu J, Langer B, Starnawski M, Kang Y (2011) Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol 29: 3968-3976.
29. Otvos Jr L, Kovalszky I, Riolfi M, Ferla R, Olah J, Sztodola A, Nama K, Molino A, Piubello Q, Wade JD, Surmacz E (2011) Efficacy of a leptin receptor antagonist peptide in a mouse model of triple-negative breast cancer. Eur J Cancer 47: 1578-1584.
30. Pai R, Lin C, Tran T, Tarnawski A (2005) Leptin activates STAT and ERK2 pathways and induces gastric cancer cell proliferation. Biochem Biophys Res Commun 331: 984-992.
31. Paik SS, Jang S, Jang K, Lee KH, Choi D, Jang SJ (2009) Leptin expression correlates with favorable clinicopathologic phenotype and better prognosis in colorectal adenocarcinoma. Ann Surg Oncol 16(2): 297-303.
32. Petit T, Wilt M, Velten M, Rodier J, Fricker J, Dufour P, Ghnassia J (2010) Semi-quantitative evaluation of estrogen receptor expression is a strong predictive factor of pathological complete response after anthracycline-based neo-adjuvant chemotherapy in hormonal-sensitive breast cancer. Breast Cancer Res Treat 124: 387-391.
33. Petty RD (2012) Exclusive rights in gastric cancer genomics. Gut 61: 638-640.
34. Pozzo C, Barone C (2008) Is there an optimal chemotherapy regimen for the treatment of advanced gastric cancer that will provide a platform for the introduction of new biological agents? Oncologist 13: 794-806.
35. Shida D, Kitayama J, Mori K, Watanabe T, Nagawa H (2005) Transactivation of epidermal growth factor receptor is involved in leptin-induced activation of janus-activated kinase 2 and extracellular signal-regulated kinase 1/2 in human gastric cancer cells. Cancer Res 65: 9159-9163.
36. Shpilman M, Niv-Spector L, Katz M, Varol C, Solomon G, Ayalon-Soffer M, Boder E, Halpern Z, Elinav E, Gertler A (2011) Development and characterization of high affinity leptins and leptin antagonists. J Biol Chem 286: 4429-4442.
37. Sun J, Han J, Ahn JS, Park K, Ahn M (2011) Significance of thymidylate synthase and thyroid transcription factor 1 expression in patients with nonsquamous non-small cell lung cancer treated with pemetrexed-based chemotherapy. J Thorac Oncol 6: 1392-1399.
38. Tan IB, Ivanova T, Lim KH, Ong CW, Deng N, Lee J, Tan SH, Wu J, Lee MH, Ooi CH, Rha SY, Wong WK, Boussioutas A, Yeoh KG, So J, Yong WP, Tsuburaya A, Grabsch H, Toh HC, Rozen S, Cheong JH, Noh SH, Wan WK, Ajani JA, Lee J, Salto-Tellez M, Tan P (2011) Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy. Gastroenterology 141: 476-485.e11.
39. VanSaun MN (2013) Molecular pathways: adiponectin and leptin signaling in cancer. Clin Cancer Res 19: 1926-1932.
40. Waddell T, Chau I, Cunningham D, Gonzalez D, Frances A, Okines C, Wotherspoon A, Saffery C, Middleton G, Wadsley J, Ferry D, Mansoor W, Crosby T, Coxon F, Smith D, Waters J, Iveson T, Falk S, Slater S, Peckitt C, Barbachano Y (2013) Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. Lancet Oncol 14: 481-489.
41. Waterworth A, Hanby A, Speirs V (2005) A novel cell array technique for high-throughput, cell-based analysis. In Vitro Cell Dev Biol Anim 41: 185-187.
42. Zhao X, Huang K, Zhu Z, Chen S, Hu R (2007) Correlation between expression of leptin and clinicopathological features and prognosis in patients with gastric cancer. J Gastroenterol Hepatol 22(8): 1317-1321.